NCT07297979
See how this trial matches your record
Connect MyChart to see which criteria your record clearly satisfies, which need a clinician’s review, and which appear to disqualify you. Your data is read in this browser tab and never sent to our servers.
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.
Chris OBrien Lifehouse
Camperdown, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Perth Childrens Hospital
Nedlands, Australia
Cedars Sinai Medical Center
Los Angeles, California
University of California Los Angeles
Los Angeles, California